November 25, 2016

Home

[cs_content][cs_section bg_image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/AngioSoma-ticker-SOAN-Penny-Stock-microscope-385364_1920.jpg” parallax=”true” class=”cs-ta-center” style=”margin: 0px;padding: 0px;”][cs_row inner_container=”false” marginless_columns=”true” bg_color=”hsla(0, 5%, 18%, 0.73)” style=”margin: 0px auto;padding: 80px 0px;”][cs_column bg_color=”hsla(0, 0%, 0%, 0.3)” fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ class=”cs-ta-center” style=”padding: 0px;”][x_custom_headline level=”h3″ accent=”false” class=”cs-ta-center mvn” style=”color: hsl(0, 2%, 97%);”]

AngioSoma Inc.

[/x_custom_headline][cs_text]

PUBLICLY-TRADED, CLINICAL STAGE BIOTECHNOLOGY COMPANY

[/cs_text][cs_text]

Ticker: SOAN

[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” style=”margin: 0px;padding: 5px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;border-style: solid;border-width: 1px;”][x_blockquote cite=”Released on October 25, 2016, Uptick Newswire’s Jasyn Blair interviewes David Summers, Ph.D.” type=”center”]Audio interview with David P. Summers Ph.D.
[/x_blockquote][/cs_column][/cs_row][/cs_section][cs_section bg_color=”hsla(0, 65%, 23%, 0)” parallax=”false” style=”margin: 0px;padding: 0px;”][cs_row inner_container=”true” marginless_columns=”false” bg_color=”hsla(0, 25%, 45%, 0)” style=”margin: 10px auto 0px;padding: 10px;”][cs_column bg_color=”hsla(0, 0%, 0%, 0)” fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px 30px;”][cs_text class=”cs-ta-justify”]Latest Event November 2016 Shareholder Presentation. View in:  PDF | PPT

AngioSoma Inc.
Ticker: SOAN
Status: Fully Reporting
SEC Reporting: Current
Latest Filing: 10Q

Business Description

AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” style=”margin: 0px;padding: 5px 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_custom_headline level=”h2″ accent=”false”]Recent News[/x_custom_headline][x_recent_posts count=”4″ offset=”” category=”” orientation=”horizontal” no_sticky=”true” no_image=”false” fade=”false”][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” style=”margin: 0px;padding: 45px 0px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_custom_headline level=”h2″ accent=”false”]Products in Pipeline[/x_custom_headline][/cs_column][/cs_row][/cs_section][cs_section bg_color=”hsla(0, 0%, 0%, 0.07)” parallax=”false” style=”margin: 0px;padding: 45px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/4″ style=”padding: 0px;”][x_feature_box title=”Liprostin” title_color=”hsla(229, 88%, 54%, 0.84)” text_color=”” graphic=”image” graphic_size=”200px” graphic_shape=”square” graphic_color=”#ffffff” graphic_bg_color=”#2ecc71″ align_h=”center” align_v=”top” side_graphic_spacing=”20px” max_width=”none” link_text=”Read More →” href=”http://s642097301.onlinehome.us/liprostin” href_title=”Liprostin Product information” href_target=”” link_color=”” graphic_image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/Liprostin-AngioSoma-Inc.png” graphic_animation=”fadeInUp” graphic_animation_offset=”70″ graphic_animation_delay=”100″]Liprostin™, AngioSoma, Inc.’s flagship product in its product pipeline, is a Peripheral Artery Disease (‘PAD‘) therapy using FDA approved Alprostadil™ (a prostaglandin, referred to as PGE-1) packaged inside a proprietary…[/x_feature_box][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/4″ style=”padding: 0px;”][x_feature_box title=”Transdermal PGE-1 Patch” title_color=”hsla(229, 88%, 54%, 0.84)” text_color=”” graphic=”image” graphic_size=”200px” graphic_shape=”square” graphic_color=”#ffffff” graphic_bg_color=”#2ecc71″ align_h=”center” align_v=”top” side_graphic_spacing=”20px” max_width=”none” link_text=”Read More →” href=”http://s642097301.onlinehome.us/transdermal-patch” href_title=”Transdermal PGE-1 Patch from AngioSoma” href_target=”” link_color=”” graphic_image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/Transdermal-PGE-1-Patch-AngioSoma-Inc.png” graphic_animation=”fadeInUp” graphic_animation_offset=”70″ graphic_animation_delay=”404″]In September 2016, AngioSoma, Inc. with its Chairman Emeritus David P. ‘Doc‘ Summers PhD filed 2 provisional U.S. Patents and 2 non-provisional U.S. Patents (announced October 11, 2016 in a press release entitled ‘AngioSoma, Inc. Files 3… [/x_feature_box][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/4″ style=”padding: 0px;”][x_feature_box title=”OmniCath” title_color=”hsla(229, 88%, 54%, 0.84)” text_color=”” graphic=”image” graphic_size=”200px” graphic_shape=”square” graphic_color=”#ffffff” graphic_bg_color=”#2ecc71″ align_h=”center” align_v=”top” side_graphic_spacing=”20px” max_width=”none” link_text=”Read More →” href=”http://s642097301.onlinehome.us/omnicath-i-omnicath-ii” href_title=”OmniCath Product information” href_target=”” link_color=”” graphic_image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/OmniCath-AngioSoma-Inc.png” graphic_animation=”fadeInUp” graphic_animation_offset=”70″ graphic_animation_delay=”800″]SOAN is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath® II. AngioSoma Research, Inc., a wholly owned Texas subsidiary, own patents associated with the OmniCath® I [/x_feature_box][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/4″ style=”padding: 0px;”][x_feature_box title=”Nutraceuticals” title_color=”hsla(229, 88%, 54%, 0.84)” text_color=”” graphic=”image” graphic_size=”200px” graphic_shape=”square” graphic_color=”#ffffff” graphic_bg_color=”#2ecc71″ align_h=”center” align_v=”top” side_graphic_spacing=”20px” max_width=”none” link_text=”Read More →” href=”http://s642097301.onlinehome.us/soma-nutraceuticals-inc” href_title=”Nutraceuticals – from AngioSoma” href_target=”” link_color=”” graphic_image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/Nutraceuticals-AngioSoma-Inc.png” graphic_animation=”fadeInUp” graphic_animation_offset=”70″ graphic_animation_delay=”1200″]These products have previously generated over ten million dollars ($10,000,000) in sales, through various sales outlets including GNC, while these products were owned and marketed by Endovasc, Inc. in 2005 and 2006:[/x_feature_box][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” style=”margin: 0px;padding: 5px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_custom_headline level=”h2″ accent=”false”]Team AngioSoma[/x_custom_headline][cs_text]AngioSoma, Inc.’s team of professionals underscores the talent that has gone into our pipeline of products as well as the ability to bring those products to value for our shareholders.[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” class=”cs-ta-center” style=”margin: 0px;padding: 5px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto 45px;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_promo image=”http://angiosoma.info/wp-content/uploads/2016/08/Alexanderia-Blankenship-2.jpg” alt=”Placeholder” class=”man”]

Alexanderia Blankenship

CEO

[x_gap size=”10px”]

Ms. Blakenship has overseen the acquisition of intellectual property consisting of multiple patents from a private corporation.

[/x_promo][x_gap size=”45px” class=”cs-hide-xl cs-hide-lg cs-hide-md”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_promo image=”http://angiosoma.info/wp-content/uploads/2016/08/David-P.-Summers.jpg” alt=”Placeholder” class=”man”]

David Summers, Ph.D.

Chairman Emeritus

[x_gap size=”10px”]

‘Doc’ Summers is our Chairman Emeritus and provides over 35 years of research and development of the products within our product pipeline.

[/x_promo][x_gap size=”45px” class=”cs-hide-xl cs-hide-lg cs-hide-md”][/cs_column][/cs_row][cs_row inner_container=”true” marginless_columns=”true” style=”margin: 0px auto 45px;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 0px;”][x_promo image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/08/SOAN-Tom-Garcia-MD.png” alt=”Placeholder” class=”man”]

A, Tomas Garcia. III, MD.

Scientific Board of Advisors

[x_gap size=”10px”]

Dr. Garcia is a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association.

[/x_promo][x_gap size=”45px” class=”cs-hide-xl cs-hide-lg cs-hide-md”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 0px;”][x_promo image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/drjackiersee-AngioSoma-200×200.jpg” alt=”Placeholder” class=”man”]

Dr. Jackie R. See, M.D.

Scientific Board of Advisors

[x_gap size=”10px”]

Dr. See is a cardiologist and the principal inventor and author of the patent corporate of microsphere technology “PGE1-EDT”.

[/x_promo][x_gap size=”45px” class=”cs-hide-xl cs-hide-lg cs-hide-md”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 0px;”][x_promo image=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/Robert-L.-Sonfield.jpg” alt=”Placeholder” class=”man”]

Robert L. Sonfield

Corporate Counsel

[x_gap size=”10px”]

With over 55 years of practice of law, Robert Leon Sonfield, Jr. esq is one of the founders of AngioSoma, Inc. as well as its corporate counsel.

[/x_promo][/cs_column][/cs_row][/cs_section][cs_section bg_color=”hsl(0, 0%, 96%)” parallax=”false” style=”margin: 0px;padding: 5px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_custom_headline level=”h2″ accent=”false”]Our Core Values For Stockholders[/x_custom_headline][/cs_column][/cs_row][/cs_section][cs_section bg_color=”hsl(0, 0%, 96%)” parallax=”true” style=”margin: 00px 0px 0px;padding: 0%;color: #fff;”][cs_row inner_container=”true” marginless_columns=”true” bg_color=”hsla(227, 93%, 49%, 0)” style=”margin: 0px auto;padding: 20px 40px 10px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_accordion][x_accordion_item title=”Audio Interview” open=”false”]Investors will want to listen to the interview with Dr. Summers.

[/x_accordion_item][x_accordion_item title=”Investors Presentation 2016″ open=”false”]

Investors can download the November 2016 Investor Presentation in PDF or as a power Point, 2000px-microsoft_powerpoint_2013_logo-svg1

PDF: soan-shareholder-presentation-september-2016

[/x_accordion_item][x_accordion_item title=”Filed Patents” open=”false”]AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™[/x_accordion_item][/x_accordion][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_accordion][x_accordion_item title=”Stock Information” open=”false”]AngioSoma Inc.
Ticker: SOAN
Status: Fully Reporting
SEC Reporting: Current
Latest Filing: 10Q
Authorized Shares: 480,000,000 (a/o Oct 23, 2016)
Outstanding Shares: 34,341,667 (a/o Oct 23, 2016)

Business Description

AngioSoma, Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD). The Company is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

[/x_accordion_item][x_accordion_item title=”FORWARD LOOKING STATEMENTS” open=”false”]AngioSoma news releases and the information provided on this website contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.[/x_accordion_item][x_accordion_item title=”Assets” open=”false”]

OUR ASSETS

AngioSoma, Inc. has a robust product pipeline, with patents, provisional patents, expired patents with corporate intellectual property / knowledge, registered trademarks, and many more to come. Here are the most important current corporate assets that contribute to our shareholder value.

LIPROSTIN™ PHARMACEUTICAL

Liprostin™ is a treatment for PAD that has completed FDA Phase I and three Phase II clinical trials. We are in discussions with contract research organizations (“CRO”) for completion of our U.S. Food and Drug Administration (“FDA”) protocol for Phase III and submission of our new drug application for marketing in the US and its territories.
TRANSDERMAL PGE-1 PATCH

The Transdermal PGE-1 Patch for the delivery of PGE-1 and / or Liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of 2 Provisional US Patents and 2 Non-Provisional US Patents filed in September 2016 by AngioSoma, Inc.
OMNICATH I & OMNICATH II

The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.
SOMA NUTRICEUTICALS, INC.

Soma Nutriceuticals, Inc. provides patented nutraceutical products that increase muscle mass as well as non-patented nutraceutical products with proprietary formulas for aiding sleep, erections, stamina, and other uses.[/x_accordion_item][/x_accordion][/cs_column][/cs_row][/cs_section][cs_responsive_text selector=”.resp-h” compression=”1.35″ min_size=”36px” max_size=”64px”][cs_responsive_text selector=”.resp-p” compression=”2.65″ min_size=”18px” max_size=”21px”][cs_responsive_text selector=”.resp-h-timeline” compression=”0.85″ min_size=”28px” max_size=”54px”][cs_responsive_text selector=”.resp-p-timeline” compression=”2.35″ min_size=”16px” max_size=”24px”][/cs_content]